GT Biopharma (NASDAQ:GTBP) Announces Quarterly Earnings Results, Misses Estimates By $0.45 EPS

GT Biopharma (NASDAQ:GTBP) announced its quarterly earnings results on Friday. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.45), FiscalAI reports.

GT Biopharma Stock Up 26.1%

GTBP traded up $0.19 during trading hours on Friday, reaching $0.92. 12,937,039 shares of the company’s stock traded hands, compared to its average volume of 528,092. The firm has a 50-day moving average price of $0.72 and a 200 day moving average price of $1.70. The firm has a market capitalization of $3.27 million, a PE ratio of -0.23 and a beta of 1.38. GT Biopharma has a 52-week low of $0.54 and a 52-week high of $4.10.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of GT Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.